DiaMedica Therapeutics Earnings Estimate

DMAC Stock  USD 4.67  0.15  3.11%   
By analyzing DiaMedica Therapeutics' earnings estimates, investors can diagnose different trends across DiaMedica Therapeutics' analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for DiaMedica Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Yuan Drop
 
Covid
DiaMedica Therapeutics is projected to generate -0.194175 in earnings per share on the 31st of December 2025. DiaMedica Therapeutics earnings estimates show analyst consensus about projected DiaMedica Therapeutics EPS (Earning Per Share). It derives the highest and the lowest estimates based on DiaMedica Therapeutics' historical volatility. Many public companies, such as DiaMedica Therapeutics, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing DiaMedica Therapeutics' earnings estimates, investors can diagnose different trends across DiaMedica Therapeutics' analyst sentiment over time as well as compare current estimates against different timeframes. The current year's Gross Profit is expected to grow to about (25.6 K). In addition to that, Pretax Profit Margin is expected to decline to -10.69Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DiaMedica Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
For information on how to trade DiaMedica Stock refer to our How to Trade DiaMedica Stock guide.

DiaMedica Therapeutics Earnings per Share Projection vs Actual

About DiaMedica Therapeutics Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of DiaMedica Therapeutics earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current DiaMedica Therapeutics estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as DiaMedica Therapeutics fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Last ReportedProjected for Next Year
Retained Earnings-140 M-133 M
Retained Earnings Total Equity-62 M-58.9 M
Earnings Yield(0.11)(0.12)
Price Earnings Ratio(8.98)(9.42)
Price Earnings To Growth Ratio(0.36)(0.34)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether DiaMedica Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of DiaMedica Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Diamedica Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Diamedica Therapeutics Stock:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DiaMedica Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
For information on how to trade DiaMedica Stock refer to our How to Trade DiaMedica Stock guide.
You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DiaMedica Therapeutics. If investors know DiaMedica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DiaMedica Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.65)
Return On Assets
(0.41)
Return On Equity
(0.67)
The market value of DiaMedica Therapeutics is measured differently than its book value, which is the value of DiaMedica that is recorded on the company's balance sheet. Investors also form their own opinion of DiaMedica Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is DiaMedica Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DiaMedica Therapeutics' market value can be influenced by many factors that don't directly affect DiaMedica Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DiaMedica Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if DiaMedica Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DiaMedica Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.